Ajmaline Challenge To Unmask Infrahisian Disease In Patients With Recurrent And Unexplained Syncope, Preserved Ejection Fraction, With Or Without Conduction Abnormalities On Surface ECG

Francesco Pentimalli, Luca Bacino, Matteo Ghione, Giambattista Siri, Massimo Gazzarata, Paolo Bellotti


Abstract

Background: Pharmacological challenge with class I antiarrhythmic drug is a recommended diagnostic test in patients with unexplained syncope only in the presence of bundle branch block, when non-invasive tests have failed to make the diagnosis. Its role in patients with minor or no conduction disturbances on 12-leads ECG has not been evaluated yet. It is also not clear which are the values of His-Ventricular interval to be considered diagnostic. We sought to evaluate the role of ajmaline challenge in unmasking the presence of an infrahisian disease in patients with recurrent and unexplained syncope, regardless of the existence of conduction disturbances on surface ECG.

Materials And Methods: Patients with history of recurrent syncope, preserved EF and a negative first level workup were enrolled. Conduction disturbances on ECG were not considered as an exclusion criteria. During EPS, basal HV conduction was determined. In the presence of a HV > 70 msec the study was interrupted and the patient was implanted with a pacemaker. If the HV was ≤ 70 msec, ajmaline was infused and HV was reassessed. The maximum value of HV was considered. A prolongation ≥ 100 msec was considered as diagnostic and indicative of conduction disease, and the patient underwent pacemaker implantation. Patients with an HV < 100 msec were implanted with an ILR.

Results: Sixteen consecutive patients were studied (age 76±5.2 years). Nine patients had conduction disturbances at baseline ECG (group ECG+). Among them, 5 had a basal diagnostic HV interval and 4 had a non-diagnostic HV interval. In the latter group, abnormal response to ajmaline was observed in 3 patients. In this group only one patient was implanted with an ILR, 8 patients were implanted with a pacemaker. Among the seven patients without conduction disturbances (group ECG-), no one had a diagnostic basal HV interval. After drug administration, 4 patients had a non-diagnostic response and were implanted with an ILR, while 3 patient had a pathological response and were implanted with a pacemaker. No difference was found in the values of maximum HV interval prolongation after ajmaline between the two groups (P = 0.89). During a mean follow up of 13±3 months, no patient has developed a syncopal episode. One patient in group ECG- and negative drug test was implanted after 3 months with a permanent pacemaker because of a two to one asymptomatic AV block at ILR interrogation.

Conclusions: Ajmaline challenge is a useful tool to unmask the presence of an infrahisian disease in patients with preserved EF, unexplained syncope and negative workup, even in the absence of conduction disturbances on 12-leads ECG. It is a simple and safe test that may disclose the detection of the disease. In these patients, an earlier pacemaker implantation of a pacemaker, may avoid the consequences of a syncopal recurrence. Values of HV interval > 70 msec in basal conditions and ≥ 100 msec after ajmaline administration seem appropriate to unmask infrahisian disease. Larger population is required to validate this hypothesis.

Introduction

Unexplained and recurrent syncope represents a diagnostic challenge for cardiologists and electrophysiologists. It is known to affect quality of life, to cause physical injuries and to be a harbinger of sudden death. The current management 1 suggests implantation of an ILR (Implantable Loop Recorder) in the presence of a normal ejection fraction, no or minimal structural heart disease, normal 12-lead ECG and negative first level work-up. Conversely, Electrophysiological Study (EPS) before implantation of an ILR is recommended only in the presence of sinus bradycardia and/or conduction disturbances on surface ECG. So far, the conduction disturbances liable of an EPS were the bundle branch block or the bifascicular block.2 EPS is a useful tool to detect atrio-ventricular conduction abnormalities, although with very low sensitivity.3,4,5,6,7 To overcome this limitation, class 1A and 1C drugs have been introduced into clinical practice.8,9,10,11,12

Ajmaline is a class 1A drug, a very powerful sodium channel blocker with relative short half-life.13 Its role in diagnostic testing is confined to two fields of application: to unmask the diagnostic electrocardiographic pattern of Brugada syndrome in the case of non-
Another unanswered issue is the use of EPS with drug test in subjects with minor conduction abnormalities, as proposed in recent new diagnostic algorithms. So far, there is no data available in the literature about the role of the test in patients with minor or even without conduction disturbances on surface ECG.

Given these premises, we sought to evaluate the feasibility, utility, safety and diagnostic role of ajmaline challenge in unmasking the presence of an infrahisian disease in patients with recurrent and unexplained syncope, with preserved ejection fraction, regardless of the existence of conduction disturbances on surface ECG.

Methods

Study Population

All consecutive patients referred to our institution between September 2014 and March 2015 were included in this study. Inclusion criteria were: a history of recurrent and unexplained syncopal episodes (2 or more syncopal episodes per year), or a single episode with severe trauma or physical injury and/or patients with syncope in high risk setting; a negative first level workup (biochemical analysis, 24-hour Holter monitoring, tilt table testing, carotid sinus massage, stress test and neurological work-up). The term “unexplained” refers to a transient loss of consciousness with abrupt onset and offset of unknown cause. Medical history, physical examination, baseline ECG and transthoracic echocardiography were obtained before any invasive procedure. Relevant structural cardiac abnormalities or severe left ventricular dysfunction were excluded. Conduction abnormalities on 12-leads ECG or the presence of atrial fibrillation were not considered as an exclusion criteria. Patients with syncope and known ischaemic heart disease underwent to coronary angiography in order to exclude the presence of new significant coronary artery disease.

Study Protocol

Patients were divided into two groups: those with a conduction disturbance on 12-leads ECG (group ECG+) and those without any conduction abnormality (group ECG-). Conduction disturbances on 12-leads ECG were defined as the presence of at least a prolongation of the PR interval above 100 msec and/or the presence of a QRS duration superior to 100 msec.

Figure 1 shows the study flow-chart. A basal EPS was performed in all cases. If the latter did not show any abnormal finding on AV conduction (HV > 70 msec, development of intra- or infra-hisian block on incremental atrial pacing) drug test with ajmaline was then performed. In any case the patient, according to the results of the previous tests, was implanted with a permanent cardiac pacemaker (PM) or an Implantable Loop Recorder (ILR).

Electrophysiological Study

Antiarrhythmic drugs, were discontinued for at least 5 half-lives before the procedure, except for amiodarone. After obtaining informed consent, two 6 French diagnostic quadripolar electrode catheters (S. Jude Medical, Minnetonka, MN, USA) were introduced via the right femoral vein using the Seldinger technique and advanced under fluoroscopic guidance to the high right atrium (HRA) and across the tricuspid valve to record the His Bundle potential. The surface electrocardiographic recordings and intracardiac electrogrograms were continuously recorded and stored on a digital recording system (EP-Workmate 4.2 System, S. Jude Medical, Minnetonka, MN, USA). Bipolar intracardiac electrogrograms were filtered between 30 and 500 KHz. Baseline conduction intervals (AH and HV) were recorded and measured at a speed of 300 mm/s. The electrophysiologic evaluation of sinus node function (if patient was in sinus rhythm) included measurements of sinus node recovery time (SNRT), corrected SNRT (cSNRT = SNRT – sinus node cycle length) and sino-atrial conduction time (SACT) estimated by the protocol described by Narula et al. Anterograde conduction was also tested with atrial incremental pacing and a programmed atrial stimulation was performed at HRA with 2 basic cycle length (500 and 400 msec) and 1, 2 or 3 atrial extrastimuli with a minimum coupling interval of 200 msec.

The quadripolar catheter at HRA was then moved into the right ventricular apex and bipolar pacing from the distal pair of electrodes was performed in order to test the capture threshold. The stimulation amplitude was set at twice the capture threshold to permit emergency stimulation, if required during the subsequent test. Retrograde conduction was tested with ventricular incremental pacing and a programmed ventricular stimulation was performed with 2 basic cycle length (500 and 400 msec) and 1, 2 or 3 ventricular extrastimuli with a minimum coupling interval of 200 msec.

Regardless of the measured basal values of the various parameters, an HV interval value was considered diagnostic only if greater than 70 msec, otherwise ajmaline challenge was performed.

Ajmaline Challenge

Ajmaline was administered intravenously at a dose of 1 mg/Kg over a 2 minutes period. Ajmaline infusion was promptly interrupted before reaching the target dose if QRS prolongation exceeded 30% compared to baseline duration, in the occurrence of frequent premature ventricular contractions (PVCs), or appearance of a type 1 Brugada ECG in right precordial leads, or in the case of development of high degree atrio-ventricular block. By the end of the infusion HV interval was constantly monitored and assessed at the 1st, 2nd, 3rd, 4th, 5th minute and then every five minutes until half an hour. The longer HV time interval at a speed of 300 mm/sec was then taken. A prolongation of the HV interval ≥100 msec was considered diagnostic and the patient was implanted with a PM. A prolongation less than 100 msec was considered non-diagnostic and the patient was implanted with ILR.

ECC And Intracardiac Recordings

All ECG tracings and intracardiac recordings were analyzed before and after ajmaline infusion by two experienced electrophysiologists and, in case of disagreement, a third physician was consulted. Heart rate, PQ interval, QRS duration, AH and HV interval, SNRT and cSNRT were measured in milliseconds.

Statistical Analysis

Data are expressed as mean ± standard deviation (SD) or as absolute.
values and percentages as appropriate. The Fisher’s exact test was used to compare categorical variables. Continuous variables between two groups were analysed using the unpaired Student’s t-test. A P-value less than 0.05 was considered for statistical significance. Statistical analyses were conducted using the SPSS software (SPSS v22, IL, USA).

Results

Baseline Characteristics

A total of 16 consecutive patients were enrolled in the study. Table 1 summarizes the baseline clinical characteristics of the population. Mean age was 76 ± 5 years (ranging from 68 to 86) and 7 were male (44%). All patients showed preserved left ventricular function on transthoracic echocardiogram, with a mean EF of 57 ± 5%. Six patients (37%) had minimal structural heart disease (defined as the presence of mild valvular disease and/or mild left ventricular hypertrophy and/or mild dilatation of the aortic bulb). One patient had history of paroxysmal atrial fibrillation. All patients were in sinus rhythm at the time of enrollment and during the EPS. One patient had history of coronary artery disease and a coronary angiography excluded the progression of new significant disease. Nine patients (56%) had a conduction disturbance and were included in the group ECG+

Table 2 shows the type of conduction disturbances on 12-leads ECG found in this group of patients. The most common was the first degree AV block associated with the left bundle branch block (3 patients, corresponding to 33%). Two patients (22%) presented with isolated right bundle branch block. There was a patient with isolated left bundle branch block and two patients with two kind of bifascicular block, respectively: one with first degree AV block associated to left anterior fascicular block and one patient with left bundle branch block. An isolated first degree AV block was present only in one patient.

Seven patients (44%) had no conduction disturbance on surface 12-leads ECG and were included in the group ECG-.

Table 3 highlights the baseline clinical characteristics of the two groups. They did not differ for the mean age (75 ± 6 years and 76 ± 5 years, P=0.96) and the mean ejection fraction (57 ± 4% and 59 ± 2%, P=0.18).

Males were more likely to have a conduction disturbance on surface ECG, although the difference was not statistically significant (P=0.06).

Mean QRS duration was significantly different between the two groups (133 ± 30 msec and 90 ± 7 msec, P <0.01) while there was a trend toward a difference in the PR interval duration (234 ± 79 msec and 174 ± 22 msec) though it did not reach a statistical difference (P= 0.07).

Evidences From Basal EPS

All 16 patients underwent the basal EPS (figure 2 and table 4). No patient had abnormal cSNRT (group ECG+ 372 ± 140 msec, group ECG- 365 ±151 msec, P=0.67) or developed intra or infrahisian block during incremental atrial pacing. All patients showed a normal response after atrial and ventricular programmed electrical stimulation. AH intervals were statistically different between the groups: mean AH intervals in group ECG+ were 155 ± 58 msec while they were 86 ± 16 msec in group ECG- (P=0.02). Basal mean HV intervals were statistically different between the two groups: they were 68 ± 12 msec in group ECG+ and 56 ± 7 msec in group ECG- (P=0.036).

Table 5 summarizes the comparison of the results of diagnostic basal HV interval between the two groups. In the group ECG+, 5 patients (56%) had a basal diagnostic HV interval with a mean value of 76 ± 6 msec, while 4 patients (44%) had a non-diagnostic HV interval (58 ± 8 msec). The difference between these baseline values reached a significant statistical difference (P < 0.01).

In the group ECG-, none had a diagnostic basal HV interval, with a mean value of 56 ± 7 msec. Of note, these values were not statistically different from those registered in the group ECG+ with non-diagnostic basal HV interval (P=0.74).

Response To Ajmaline Challenge And Side Effects

Eleven patients, of which 4 in the group ECG+ and 7 in the group ECG-, underwent drug test with ajmaline. All patients were tested with the maximal dose required to complete the challenge, and there was no premature interruption of the drug infusion. No side effects were recorded during drug administration. Of the four patients in the group ECG+, 3 (75%) developed a diagnostic interval with a mean HV of 108 ± 2 msec (Table 5). In the group ECG-, three patients (43%) showed a diagnostic HV interval, with a mean value 108 ± 8 msec. It is noteworthy that the mean maximum value of HV interval reached during a positive challenge is not statistically different between the two groups (P=0.89).

Finally, when properly evaluable, no patients developed a Brugada type 1 on right precordial leads during the test.

Implantation

After the protocol application (EPS + drug challenge), a total of eleven patients (69%) were implanted with a permanent pacemaker while five patients (31%) underwent an ILR implantation.

Among the patients implanted with a PM: 8 belonged to the group ECG+, of which 5 after a basal EPS and 3 after the drug challenge; and 3 belonged to the group ECG-. The protocol unmasked an infrahisian disease in 89% of patients with ECG+ and in 43% of patients in group ECG-. Finally, five patients were implanted with an ILR (31%): 1 in the group ECG+ and 4 in the group ECG-.

Patient implanted with a pacemaker received appropriate devices for their conditions. Some patients in the group ECG+ and all patients in the group ECG- were implanted with pacemakers equipped with algorithms aimed at reducing the ventricular pacing percentage, such as the Managed Ventricular Pacing26 and the SafeR.27 In the latter case, it is possible to review retrospectively, into pacemaker memory,
Baseline clinical characteristics of study population (N = 16)

<table>
<thead>
<tr>
<th>Age (years), mean ± SD</th>
<th>76 ± 5</th>
</tr>
</thead>
<tbody>
<tr>
<td>Males</td>
<td>7 (44)</td>
</tr>
<tr>
<td>Associated structural heart diseases:</td>
<td></td>
</tr>
<tr>
<td>Any abnormality</td>
<td>10 (62.5)</td>
</tr>
<tr>
<td>Ischemic</td>
<td>1 (6.25)</td>
</tr>
<tr>
<td>Valvular</td>
<td>5 (31)</td>
</tr>
<tr>
<td>Hypertensive</td>
<td>2 (12.5)</td>
</tr>
<tr>
<td>Other</td>
<td>2 (12.5)</td>
</tr>
<tr>
<td>LV ejection fraction (%), mean ± SD</td>
<td>57 ± 5</td>
</tr>
<tr>
<td>ECG conduction disturbances</td>
<td>9 (56)</td>
</tr>
<tr>
<td>Sinus Rhythm at EPS</td>
<td>18 (100)</td>
</tr>
<tr>
<td>History of paroxysmal/persistent AF</td>
<td>1 (6.25)</td>
</tr>
</tbody>
</table>

Data are expressed as No. (%) unless otherwise specified.

Follow-Up

A mean follow up of 13 ± 3 months was available for all patients. Follow-up was not statistically different among the two groups (P=0.85). Patients in the group ECG+ had no recurrence of syncopal episodes and one patient died because of a cerebral neoplasia.

In the group ECG – there was no recurrence of syncyne in any patient. One of them showed, on ILR memory, an asymptomatic episode of two to one AV block and was consequently implanted with a permanent pacemaker.

Analysis of stored pacemaker data in patients implanted in both groups demonstrated the occurrence of various types of paroxysmal AV block (type 2, advanced and complete AV block). In particular, among the patients belonging to the group ECG-, the retrospective analysis of the EGM stored into pacemaker memory showed that all of them (n = 3, 100%) had the occurrence of the above mentioned types of AV block, with regular activation of ventricular pacing back-up algorithms.

Discussion

To the best of our knowledge, this is the first report of the use of ajmaline challenge in unmasking the presence of an infrahisian disease in patients with recurrent and unexplained syncope, preserved ejection fraction and no conduction disturbances on surface ECG.

The use of drug stress test during EPS in current guidelines is a class IIb level B indication in patients with 12-lead ECG bundle branch block, when non-invasive tests failed to make the diagnosis. In patients with normal ECG, no structural heart disease and no palpitations, EPS is a Class III Level B indication. However, very recently, Rosanio et al proposed a diagnostic algorithm according to which the presence of a Type 1 AV block can be considered an indication to perform EPS. Consequently, it can be noticed a trend toward a theoretical extension of the use of the EPS. However, nowadays only 2% of patients with unexplained syncope assessed by cardiologists undergo to EPS, and even fewer if they are evaluated by other specialists.

Another thorny issue is represented by the lack of standardized diagnostic values of HV time during a basal EPS or after a drug stress test. Moreover, some of these studies were conducted before the era of primary prevention of sudden cardiac death, and consequently patients with left ventricular dysfunction were included. Enormous clarity and great strides have been made in the ISSUE Study, where Moya and colleagues enrolled patients with unexplained syncope after a complete negative workup, including an EPS. Patients were implanted with an ILR and divided into four groups according to their basal condition: syncope alone, syncope alone and positive tilt test, syncope associated to bundle branch block and negative EPS and, at last, patients with structural heart disease and negative EPS. The group with bundle branch block and negative EPS consisted of 52 patients. Criteria to consider diagnostic the EPS were a basal HV interval ≥ 70 msec and the development of 2nd or 3rd degree infrahisian block after ajmaline infusion. During the follow-up authors recorded 21 asystolic pauses, of which 17 were AV blocks and four were sinus pauses. This means that 1/3 of patients were false negative at EPS, as expected by the low sensitivity of the exam but also taking into account the high specific values considered in that study. Still in the ISSUE study, if we consider the group of isolate syncope and the tilt positive group, only 66% of patients had undergone an EPS. After a mean follow-up of 9 ± 5 and 10 ± 5 months, of the 16 asystolic pauses detected, 14 were sinus arrests and only 2 (1.8%) were AV blocks. Here EPS seems to be more sensitive than the third group, especially towards the AV block. But it has to be kept in mind that only 2/3 of patient underwent an EPS with the aforementioned criteria of positivity.

In a recent study, Conte and colleagues used ajmaline challenge in elderly patients to unmask atrio-ventricular conduction disease and/or the typical Brugada ECG pattern. No values of basal HV interval to be considered diagnostic for conduction disease are reported. After ajmaline infusion they considered a response abnormal only when the prolongation of HV exceeded 100 msec.

In our study, the application of the protocol with less severe diagnostic criteria during ajmaline challenge, ensured a prompt diagnosis in the group ECG+ in 8 over 9 patients (89%). With the same criteria, in 3 over 7 patients (43%) in the group of patients with normal ECG, a diagnosis was reached. The instrumental follow-up at pacemaker interrogation, with events of various kinds of paroxysmal AV block stored, including complete AV block, demonstrates that the mechanism of the syncopal episodes occurring before EPS and PM implantation were cardiogenic and caused by severe brady-arrhythmias. Although the very small population studied in the group ECG-, no false positives emerged during the follow-up.

As expected, the sensitivity of the EPS without ajmaline was very low in patients with ECG conduction abnormalities. The use of ajmaline significantly improved the sensitivity of the EPS in this group. This is in line with what has been described previously.

<table>
<thead>
<tr>
<th>Type of conduction disturbances on surface ECG in the group ECG+ (PR interval ≥ 200 msec and/or QRS duration &gt; 100 msec)</th>
</tr>
</thead>
<tbody>
<tr>
<td>First degree AV Block</td>
</tr>
<tr>
<td>RBBB</td>
</tr>
<tr>
<td>LBBB</td>
</tr>
<tr>
<td>First degree AV block + LAFB</td>
</tr>
<tr>
<td>RBBB + LAFB</td>
</tr>
<tr>
<td>First degree AV block + LBBB</td>
</tr>
</tbody>
</table>

Data are expressed as No. (%)
However, we intentionally included in the group ECG+ patients with any conduction abnormality on surface ECG. According to our inclusion criteria, we studied some patients that, considering the last guidelines, would have directly implanted an ILR. In the light of this result, it seems that the sensitivity reported here is higher than that reported up to now in the literature, and it exceeds 95%. In fact, in the group ECG+, the only patient implanted with an ILR showed an isolated PR prolongation on surface ECG.

The results in patients without any conduction disorder (ECG -) are rather surprising. First of all, the sensitivity of the EPS without ajmaline verges on zero. Ajmaline helps improving the sensitivity and unMASKS the presence of an infranodal disease, which could not have been proved in any other way. Furthermore, the most surprising result is that the mean maximum value of HV interval reached during a positive ajmaline challenge is not statistically different between this group of patients and that registered in the group ECG+. In other words, it seems to be independent of the presence of a conduction disturbance on surface ECG.

These findings allow us to speculate that diagnostic HV interval values considered here are provided with sufficient sensitivity and specificity, but further studies with larger population are required to support this speculation.

One possible explanation of our results was the selection during the anaesthesia, with considerable attention to the clinical features of syncopal episodes. We enrolled patients with two or more syncopal episodes per year, or patients with a single episode but with physical injury. In both cases, and with the limits and difficulties often correlated with anamnesis, it was assumed that with some specific clinical features, the syncope was of cardiogenic nature.

Furthermore, we are aware that the diagnostic role of this test is highly dependent on the basis of the clinical features of syncopal episodes. In fact, from a clinical point of view, we found that the presence of a previous history of injury secondary to syncope and patients of female sex were more likely to have a positive result and therefore to implant a pacemaker, regardless of the presence of ECG conduction disturbance. This findings confirm those of a recent retrospective study. Ahmed and colleagues studied the clinical predictors of pacemaker implantation in 200 patients suffering from unexplained syncope receiving an ILR. Of the 33 patients with clinical significant bradycardia requiring PM implantation, history of injury secondary to syncope was found to be the strongest independent predictor for PM implantation, regardless of the presence of 12-lead ECG conduction abnormalities. Female sex was another strong predictor, but only in patients with ECG conduction disturbances.

Despite in the ISSUE study only 1% of patients experienced a severe injury due to syncopal relapse, a potential advantage of EPS in this setting is to unmask infranodal disease, avoiding the implantation of an ILR and thus the traumatic consequences of syncope recurrence.

In our study, ajmaline challenge proved to be a safe procedure. Ajmaline has a very rapid effect, usually in the first 2-3 minutes after the end of infusion. Pharmacokinetics studies show that the duration of electrophysiological effects is short (about 30 minutes), in comparison with the slow decay of plasma concentrations (half-life of 7.3 ± 3.6 hours), so that it is believed that a threshold concentration exists under which no drug effect can be detected. We did not record any ventricular arrhythmias during the drug challenge nor any transient second or third degree AV block. Nevertheless, ajmaline infusion has to be performed in an appropriate environment, with advanced life-support facilities available, as external defibrillator and ventricular back-up pacing.

**Table 4: Parameters at basal EPS (N = 16)**

<table>
<thead>
<tr>
<th>Parameter</th>
<th>ECG + (n = 9)</th>
<th>ECG - (n = 7)</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>cSNRT (msec)</td>
<td>372 ± 140</td>
<td>365 ± 151</td>
<td>0.67</td>
</tr>
<tr>
<td>AH (msec)</td>
<td>155 ± 68</td>
<td>86 ± 16</td>
<td>0.02</td>
</tr>
<tr>
<td>HV (msec)</td>
<td>68 ± 12</td>
<td>56 ± 7</td>
<td>0.036</td>
</tr>
</tbody>
</table>

Data are expressed as mean ± SD, unless otherwise specified.

**Table 5: Comparison of basal HV interval (A) and stress HV interval (B)**

<table>
<thead>
<tr>
<th>HV Interval</th>
<th>ECG +</th>
<th>ECG -</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Basal</td>
<td>58 ± 8 msec</td>
<td>58 ± 8 msec</td>
<td>0.74</td>
</tr>
<tr>
<td>Stress</td>
<td>108 ± 8 msec</td>
<td>108 ± 8 msec</td>
<td>0.89</td>
</tr>
</tbody>
</table>

Data are expressed as mean ± SD.

**References**


